Inhibition of bone erosion, determined by high-resolution peripheral quantitative computed tomography (hr-pqct), in rheumatoid arthritis patients receiving a conventional synthetic disease-modifying anti-rheumatic drug (csdmard) plus denosumab vs csdmard therapy alone: an open-label, randomized, parallel-group study

HIGHLIGHTS

• who: Naoki Iwamoto from the (EULAR), June, Copenhagen, DenmarkPreventive Medical Sciences, Nagasaki University Graduate School have published the paper: Inhibition of bone erosion, determined by high-resolution peripheral quantitative computed tomography (HR-pQCT), in rheumatoid arthritis patients receiving a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) plus denosumab vs csDMARD therapy alone: an open-label, randomized, parallel-group study, in the Journal: (JOURNAL)
• what: The aim of this study was to compare the inhibition of bone erosion progression in RA patients treated with a csDMARDs plus denosumab versus csDMARD therapy alone . Although the study . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.